Nearly half of the newly added drugs are Class 1 new drugs! The 2025 National Reimbursement Drug List results unveiled: All five CAR-T therapies achieve commercial insurance breakthroughs, marking the entry of innovative drug payment into the 'value era'

China's 2025 national negotiation added 114 drugs to the National Medical Insurance Drug Catalog (50 Class I new drugs) and created a new commercial insurance innovation drug catalog with 19 entries, including all five CAR‑T products; Hengrui Pharma secured inclusion for 10 drugs and Innovent Bio for seven. The overall success rate was 88% (up from 76% in 2024), the total catalog rises to 3,253 drugs, and prior negotiated drugs have driven medical insurance fund spending above RMB 460 billion; estimated patient savings exceed RMB 50 billion in 2025. The policy signals stronger state support for genuine innovation and creates new commercial/payment pathways for high‑value therapies, while implementation and payment sustainability of the commercial insurance mechanism remain key execution risks for investors.

Analysis

Market structure: Winners are large innovators with negotiated access—Hengrui (600276.SH), Innovent (01801.HK) and listed CAR‑T developers (e.g., CARsgen 02171.HK, Fosun Kite) plus multinational makers of Alzheimer’s drugs (PFE, LLY, JNJ) because reimbursement expands addressable market and de‑risk commercialization. Losers include small/mid domestic players reliant on high ASPs without insurance inclusion and generic/price‑sensitive manufacturers facing continued ~60% historical negotiation pressure; expect gross‑margin dispersion to widen 500–1,500 bps across firms over 12–24 months.

Risk assessment: Tail risks — failed implementation of the commercial insurance channel, provincial rollouts delayed beyond Dec 31, 2025, or first‑year uptake <20–30% would materially cut revenue forecasts (downside 30–70% for single‑product developers). Immediate catalysts: provincial listings by end‑Dec 2025 and hospital formulary decisions through Q1 2026; medium term (6–24 months) risks include manufacturing bottlenecks for CAR‑T and further NHSA price renegotiations.

Trade implications: Tactical longs — biased to announced winners with 6–18 month horizons: Innovent and Hengrui for diversified product flows; selective long exposure to CAR‑T developers using defined‑risk option call spreads to cap losses. Pair trades: long CAR‑T developer (growth/monopoly potential) vs short PD‑1 pure‑play domestic midcaps (value capture likely limited); size positions 1–3% portfolio per idea, reweight after provincial adoption data.

Contrarian angles: Consensus may overestimate uptake speed — commercial insurance list inclusion does not guarantee hospital adoption or utilization (historical PD‑1 rollouts showed slow prescribing despite listing). Valuations for CAR‑T names could be overbaked if first‑year uptake <25% or >50% of provinces delay implementation; set hard stop‑loss/trigger rules tied to empirical hospital uptake (see decisions).

Key Decisions for Investors

• Establish a 2–3% long position in Innovent Biologics (01801.HK) within 2 weeks, target +30–50% upside over 12 months driven by expanded indications; trim half if provincial listings <60% by Dec 31, 2025 or Q1 2026 revenue misses >20%.
• Establish a 1.5–2% long position in Hengrui (600276.SH) to capture diversified insured product sales; use a 20% stop‑loss and reassess after Q1 2026 hospital uptake metrics (reduce to 0.5% if inpatient adoption <40 hospitals for key products).
• Take a defined‑risk 1% position in CARsgen (02171.HK) via a 6‑month call spread (buy ATM, sell 25–30% OTM) to play commercial insurance enabling CAR‑T uptake; exit or flip to short if first‑year uptake <25% or manufacturing constraints cap quarterly deliveries by >30% versus guidance.
• Allocate 0.5–1% each to PFE and LLY long calls (3–6 month expiries) to play Alzheimer’s commercial insurance inclusion; target +20–40% move, sell 50% on provincial coverage confirmation or if payer utilization controls (stringent prior‑auth) are announced.
• Short or underweight PD‑1 pure‑play domestic midcaps (aggregate 1–2% net exposure) and pair with long CAR‑T/innovator names (1:1 notional) because PD‑1 class access is capped and price pressure persists; close the pair if NHSA signals further expansion of commercial insurance beyond catastrophic diseases.